Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ernexa Therapeutics (ERNA) Gross Profit (2016 - 2024)

Historic Gross Profit for Ernexa Therapeutics (ERNA) over the last 13 years, with Q4 2024 value amounting to $1000.0.

  • Ernexa Therapeutics' Gross Profit rose 10204.08% to $1000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $486000.0, marking a year-over-year increase of 38928.57%. This contributed to the annual value of $486000.0 for FY2024, which is 38928.57% up from last year.
  • As of Q4 2024, Ernexa Therapeutics' Gross Profit stood at $1000.0, which was up 10204.08% from $547000.0 recorded in Q3 2024.
  • Ernexa Therapeutics' 5-year Gross Profit high stood at $1.4 million for Q1 2020, and its period low was -$69000.0 during Q3 2023.
  • Moreover, its 3-year median value for Gross Profit was -$31000.0 (2024), whereas its average is $220250.0.
  • In the last 5 years, Ernexa Therapeutics' Gross Profit crashed by 5686.98% in 2020 and then soared by 89275.36% in 2024.
  • Ernexa Therapeutics' Gross Profit (Quarter) stood at $1.4 million in 2020, then tumbled by 103.39% to -$49000.0 in 2023, then skyrocketed by 102.04% to $1000.0 in 2024.
  • Its last three reported values are $1000.0 in Q4 2024, $547000.0 for Q3 2024, and -$48000.0 during Q2 2024.